Overview

A Study of IMO-2125 in Combination With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301)

Status:
Terminated
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
A Phase 3 comparison of ipilimumab with and without IMO-2125 in advanced melanoma
Phase:
Phase 3
Details
Lead Sponsor:
Idera Pharmaceuticals, Inc.
Collaborator:
Bristol-Myers Squibb
Treatments:
Antibodies, Monoclonal
Ipilimumab